I. MODIFIED AGREEMENTS | |||
Company* |
Company* |
Change from original |
Terms/Details (Date) |
| | |||
AltaRex Corp. (Canada; TSE:AXO) |
United Therapeutics Corp. (UTHR) |
Expanded agreement for the territory granted to United under an existing agreement to include Germany |
The agreement grants United the right to certain AltaRex products including Ova- Rex, BrevaRex, ProstaRex and GivaRex; United made an initial payment and agreed on milestone payments for the Germany license; it also agreed to the same royalty payment structure in Germany as the U.S. and other countries (8/12) |
CV Therapeutics Inc. (CVTX) |
Innovex Inc. (INVX) |
Renegotiated agreement returning all rights associated with the chronic angina candidate Ranexa to CV Therapeutics |
CV Therapeutics has agreed to issue Innovex warrants for 200,000 shares; the companies signed the original marketing and sales deal in 1999; the companies will retain a commercialization service relationship and Innovex will become a preferred provider of pharmaceutical services for CV Therapeutics (7/11) |
Epimmune Inc. (EPMN) |
Immuno Designed Molecules SA* (France) |
Exercised option to a non-exclusive license tocertain cancer epitopes for use in IDM's ex vivo cell therapy program |
Epimmune received a license fee in connection with IDM exercising the option and is entitled to receive pre-commercialization milestones and royalties on product sales; the territory is worldwide except for Japan (7/8) |
ICN Pharmaceuticals Inc. (NYSE:ICN) |
Senetek plc (SNTK) |
Expanded licensing agreement for ICN's Kinerase product line |
The new license covers kinetin-containing products in North America, Europe and Australia; the expanded contract adds five products to the Kinerase line, including new serum and cream formulations with stabilized vitamin C (8/13) |
Seattle Genetics Inc. (SGEN) |
Genencor International Inc. (GCOR) |
Extended and modified collaboration for a non- exclusive license to Seattle Genetics' antibody-directed enzyme prodrug therapy technology for use with multiple targets |
The agreement is extended for two more years; Genencor will co-fund a portion of Seattle Genetics' prodrug program in support of Genencor's drug discovery efforts (7/29) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange. | |||
